[{"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-001", "question": "A 3-week-old infant presents after an apparent life-threatening event with prolonged apnea requiring bag-mask ventilation. Polysomnography demonstrates profound hypoventilation during sleep with PaCO2 >60 mmHg. Genetic testing reveals a heterozygous non-polyalanine repeat expansion mutation in PHOX2B. Which of the following is the most appropriate next step in management?", "options": ["Initiate non-invasive ventilation with backup rate of 12 breaths/min and pressure support of 10 cm H2O", "Perform rectal suction biopsy to evaluate for Hirschsprung disease before initiating ventilation", "Initiate non-invasive ventilation with backup rate >20 breaths/min and avoid all opioid analgesics", "Prescribe supplemental oxygen at 0.5 L/min and schedule genetic counseling", "Admit for 24-hour video EEG to rule out seizure disorder"], "answer": "C", "answer_index": 2, "explanation": "Congenital central hypoventilation syndrome with non-polyalanine PHOX2B mutations requires aggressive ventilatory support with backup rates >20 breaths/min to prevent hypercapnia-induced neuronal injury. These patients have extreme sensitivity to sedatives, particularly opioids, which can precipitate fatal apnea. While Hirschsprung disease is associated with certain PHOX2B mutations, it does not precede the need for immediate ventilatory support. Standard backup rates of 12 are insufficient, and oxygen alone worsens hypoventilation.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: Correct best answer. Key stem clues: 3-week-old infant, apparent life-threatening event, prolonged apnea, polysomnography showing profound hypoventilation with PaCO2 >60 mmHg, heterozygous non-polyalanine repeat expansion PHOX2B mutation. These indicate severe congenital central hypoventilation syndrome (CCHS) requiring immediate aggressive ventilatory support. The answer C (NIV with backup rate >20 breaths/min and opioid avoidance) aligns with guideline recommendations for NPARM CCHS. Alternative options are inferior: A’s backup rate of 12 is insufficient; B delays ventilation; D provides inadequate support; E addresses seizures, not hypoventilation. No internal contradictions; a single best answer is defensible. Medical accuracy: The item correctly reflects that NPARM PHOX2B mutations cause severe CCHS needing high backup rates and opioid avoidance. Minor terminology note: “non-polyalanine repeat expansion” could be clarified as NPARM. Minimal fix: Insert ‘(NPARM)’ after the mutation description to enhance precision.\",\n\"medical_accuracy_score\":  \t \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: 3-week-old infant, apparent life-threatening event, prolonged apnea, polysomnography showing profound hypoventilation with PaCO2 >60 mmHg, heterozygous non-polyalanine repeat expansion PHOX2B mutation. These indicate severe congenital central hypoventilation syndrome (CCHS) requiring immediate aggressive ventilatory support. The answer C (NIV with backup rate >20 breaths/min and opioid avoidance) aligns with guideline recommendations for NPARM CCHS. Alternative options are inferior: A’s backup rate of 12 is insufficient; B delays ventilation; D provides inadequate support; E addresses seizures, not hypoventilation. No internal contradictions; a single best answer is defensible. Medical accuracy: The item correctly reflects that NPARM PHOX2B mutations cause severe CCHS needing high backup rates and opioid avoidance. Minor terminology note: “non-polyalanine repeat expansion” could be clarified as NPARM. Minimal fix: Insert ‘(NPARM)’ after the mutation description to enhance precision.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-002", "question": "A term neonate develops refractory seizures on day 2 of life. The mother received isoniazid 300 mg daily throughout pregnancy for latent tuberculosis. Standard anticonvulsants have failed to control the seizures. Which of the following is the most appropriate immediate management?", "options": ["Administer pyridoxine 50 mg IV once and continue phenobarbital", "Initiate continuous video-EEG monitoring and administer pyridoxine 100 mg IV every 6 hours", "Perform emergent MRI brain to evaluate for structural lesions", "Administer pyridoxal-5-phosphate 30 mg/kg/day and discontinue all other anticonvulsants", "Obtain lumbar puncture to evaluate for meningitis before initiating specific therapy"], "answer": "B", "answer_index": 1, "explanation": "Isoniazid use during pregnancy causes pyridoxine deficiency in neonates, leading to refractory seizures that respond only to high-dose pyridoxine replacement. The diagnosis requires continuous EEG monitoring to document response to therapy, as clinical improvement may be delayed. A single 50 mg dose is insufficient, and pyridoxal-5-phosphate is the active form but not the standard initial therapy. Delaying specific therapy for imaging or LP risks ongoing seizure-induced brain injury.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict: The keyed answer B is the correct best answer. Key stem clues: maternal isoniazid use throughout pregnancy, refractory neonatal seizures on day 2, failure of standard anticonvulsants. These point to pyridoxine deficiency as the etiology. The most appropriate immediate management is high‑dose pyridoxine (100 mg IV every 6 h) together with continuous video‑EEG to document response, as clinical improvement may be delayed. Option A provides an insufficient single dose; C and E delay specific therapy; D uses the active metabolite but is not standard initial therapy and suggests stopping all anticonvulsants, which is unsafe. No internal contradictions or missing critical details prevent a single best answer. Medical accuracy: The vignette and answer align with current neonatal neurology consensus and AAP guidelines on isoniazid‑induced pyridoxine deficiency seizures. The dose and monitoring recommendation are appropriate. No major inaccuracies or safety concerns. Minimal fix: None required; the item is well‑constructed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: The keyed answer B is the correct best answer. Key stem clues: maternal isoniazid use throughout pregnancy, refractory neonatal seizures on day 2, failure of standard anticonvulsants. These point to pyridoxine deficiency as the etiology. The most appropriate immediate management is high‑dose pyridoxine (100 mg IV every 6 h) together with continuous video‑EEG to document response, as clinical improvement may be delayed. Option A provides an insufficient single dose; C and E delay specific therapy; D uses the active metabolite but is not standard initial therapy and suggests stopping all anticonvulsants, which is unsafe. No internal contradictions or missing critical details prevent a single best answer. Medical accuracy: The vignette and answer align with current neonatal neurology consensus and AAP guidelines on isoniazid‑induced pyridoxine deficiency seizures. The dose and monitoring recommendation are appropriate. No major inaccuracies or safety concerns. Minimal fix: None required; the item is well‑constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-003", "question": "A 4-year-old child with Williams syndrome is scheduled for cardiac catheterization to evaluate supravalvular aortic stenosis. Preoperative echocardiography demonstrates diffuse coronary artery narrowing. The child has a history of hypercalcemia managed with dietary restriction. Which anesthetic agent is most contraindicated in this patient?", "options": ["Sevoflurane due to risk of malignant hyperthermia", "Propofol due to risk of propofol infusion syndrome", "Ketamine due to risk of exacerbating hypercalcemia", "Dexmedetomidine due to risk of severe bradycardia", "Isoflurane due to risk of coronary steal phenomenon"], "answer": "E", "answer_index": 4, "explanation": "Williams syndrome patients with coronary artery stenosis are at high risk for myocardial ischemia. Isoflurane causes coronary vasodilation and can precipitate coronary steal in patients with fixed stenotic lesions, potentially causing fatal arrhythmias. While sevoflurane is generally safe, all volatile anesthetics should be used cautiously. The hypercalcemia in Williams syndrome is not exacerbated by ketamine, and dexmedetomidine-induced bradycardia is manageable. Propofol infusion syndrome is rare with single-bolus dosing.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\": The question asks which anesthetic is most contraindicated in a 4-year-old with Williams syndrome, supravalvular aortic stenosis, diffuse coronary artery narrowing, and a history of hypercalcemia. The key discriminating finding is diffuse coronary artery stenosis, which creates a risk of myocardial ischemia. The keyed answer (E) is isoflurane due to coronary steal. Isoflurane is known to cause coronary vasodilation and can produce coronary steal in patients with fixed stenotic lesions, making it a reasonable choice for most contraindicated agent in this context. However, sevoflurane (A) is also a volatile anesthetic and could theoretically cause similar issues, though the item claims it is \\\"generally safe.\\\" The rationale that \\\"all volatile anesthetics should be used cautiously\\\" undermines the uniqueness of isoflurane as the *most* contraindicated. Ketamine (C) is not known to exacerbate hypercalcemia, dexmedetomidine (D) bradycardia is manageable, and propofol infusion syndrome (B) is rare with bolus dosing. The stem does not provide enough detail to definitively separate isoflurane from sevoflurane regarding coronary steal risk in children with Williams syndrome. This creates a situation where multiple agents could be argued as contraindicated, but isoflurane remains the best answer given its stronger evidence for coronary steal compared to sevoflurane. The item is logically valid but contains minor oversimplification regarding volatile anesthetic differences.\\n\\nValidity label: V (Valid) - The item supports a unique best answer and the key matches it, though the rationale could be more precise about distinguishing between volatile agents. The clinical scenario is consistent with established knowledge that isoflurane poses greater coronary steal risk than sevoflurane in patients with fixed coronary lesions. No major medical inaccuracies, though the statement that sevoflurane is \\\"generally safe\\\" in this specific population is an oversimplification. The hypercalcemia history is a red herring appropriately addressed. The item tests an important anesthesia consideration in a high-risk pediatric cardiac condition.\\n\\nMinimal fix: Change option A to \\\"Sevoflurane due to risk of coronary steal phenomenon\\\" to force discrimination between volatile agents, or modify the stem to specify \\\"which of the following is MOST likely to cause coronary steal\\\" rather than \\\"most contraindicated.\\\"\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ": The question asks which anesthetic is most contraindicated in a 4-year-old with Williams syndrome, supravalvular aortic stenosis, diffuse coronary artery narrowing, and a history of hypercalcemia. The key discriminating finding is diffuse coronary artery stenosis, which creates a risk of myocardial ischemia. The keyed answer (E) is isoflurane due to coronary steal. Isoflurane is known to cause coronary vasodilation and can produce coronary steal in patients with fixed stenotic lesions, making it a reasonable choice for most contraindicated agent in this context. However, sevoflurane (A) is also a volatile anesthetic and could theoretically cause similar issues, though the item claims it is \"generally safe.\" The rationale that \"all volatile anesthetics should be used cautiously\" undermines the uniqueness of isoflurane as the *most* contraindicated. Ketamine (C) is not known to exacerbate hypercalcemia, dexmedetomidine (D) bradycardia is manageable, and propofol infusion syndrome (B) is rare with bolus dosing. The stem does not provide enough detail to definitively separate isoflurane from sevoflurane regarding coronary steal risk in children with Williams syndrome. This creates a situation where multiple agents could be argued as contraindicated, but isoflurane remains the best answer given its stronger evidence for coronary steal compared to sevoflurane. The item is logically valid but contains minor oversimplification regarding volatile anesthetic differences.\n\nValidity label: V (Valid) - The item supports a unique best answer and the key matches it, though the rationale could be more precise about distinguishing between volatile agents. The clinical scenario is consistent with established knowledge that isoflurane poses greater coronary steal risk than sevoflurane in patients with fixed coronary lesions. No major medical inaccuracies, though the statement that sevoflurane is \"generally safe\" in this specific population is an oversimplification. The hypercalcemia history is a red herring appropriately addressed. The item tests an important anesthesia consideration in a high-risk pediatric cardiac condition.\n\nMinimal fix: Change option A to \"Sevoflurane due to risk of coronary steal phenomenon\" to force discrimination between volatile agents, or modify the stem to specify \"which of the following is MOST likely to cause coronary steal\" rather than \"most contraindicated.\"", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-004", "question": "A 7-year-old boy with X-linked chronic granulomatous disease presents with persistent fever and right tibial pain despite broad-spectrum antibiotics. MRI demonstrates osteomyelitis. Biopsy cultures grow Aspergillus nidulans. The patient is on prophylactic interferon-gamma 50 mcg/m² three times weekly. Which of the following is the most appropriate management?", "options": ["Increase interferon-gamma to 100 mcg/m² and add voriconazole", "Discontinue interferon-gamma and initiate liposomal amphotericin B alone", "Continue interferon-gamma and initiate voriconazole with therapeutic drug monitoring", "Switch to interferon-alpha and add caspofungin", "Continue current prophylaxis and add oral itraconazole"], "answer": "C", "answer_index": 2, "explanation": "Aspergillus nidulans is uniquely virulent in CGD and requires aggressive antifungal therapy with voriconazole, which has superior activity against this species compared to amphotericin B. Interferon-gamma prophylaxis should be continued as it enhances neutrophil function and improves outcomes. Therapeutic drug monitoring is essential as CGD patients have altered voriconazole metabolism. Interferon-alpha is not used in CGD, and itraconazole has variable absorption and inferior efficacy against A. nidulans.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: Correct best answer. Key stem clues: 7-year-old with X-linked CGD, persistent fever, tibial osteomyelitis with Aspergillus nidulans on culture, currently on interferon‑γ prophylaxis. These findings point to invasive aspergillosis in a CGD host, for which voriconazole is first‑line therapy and interferon‑γ prophylaxis should be continued. The answer C (continue interferon‑γ, start voriconazole with therapeutic drug monitoring) aligns with IDSA guidelines and CGD management recommendations. Options A and E propose dose escalation or itraconazole, which are not preferred; B discontinues interferon‑γ; D uses interferon‑α, which is not indicated. No internal contradictions or missing critical details prevent a single best choice. Medical accuracy: the explanation correctly notes voriconazole’s superiority for A. nidulans, the benefit of continued interferon‑γ, and the need for TDM in CGD patients. No safety concerns. Minimal fix: explicitly state in the stem that therapeutic drug monitoring for voriconazole is available, reinforcing the TDM component of the correct answer.\",\n\"medical_accuracy_score\":  \t\t \t \t \t \t \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: 7-year-old with X-linked CGD, persistent fever, tibial osteomyelitis with Aspergillus nidulans on culture, currently on interferon‑γ prophylaxis. These findings point to invasive aspergillosis in a CGD host, for which voriconazole is first‑line therapy and interferon‑γ prophylaxis should be continued. The answer C (continue interferon‑γ, start voriconazole with therapeutic drug monitoring) aligns with IDSA guidelines and CGD management recommendations. Options A and E propose dose escalation or itraconazole, which are not preferred; B discontinues interferon‑γ; D uses interferon‑α, which is not indicated. No internal contradictions or missing critical details prevent a single best choice. Medical accuracy: the explanation correctly notes voriconazole’s superiority for A. nidulans, the benefit of continued interferon‑γ, and the need for TDM in CGD patients. No safety concerns. Minimal fix: explicitly state in the stem that therapeutic drug monitoring for voriconazole is available, reinforcing the TDM component of the correct answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-005", "question": "A 2-month-old infant presents with delayed separation of the umbilical cord (>3 weeks), severe leukocytosis (WBC 80,000), and recurrent skin infections. Flow cytometry shows absent CD18 expression. Genetic testing confirms ITGB2 mutation. Which of the following is the most appropriate management?", "options": ["Initiate prophylactic antibiotics and schedule stem cell transplant after 1 year of age", "Perform urgent stem cell transplant before onset of severe infections", "Initiate granulocyte colony-stimulating factor and delay transplant until 5 years of age", "Treat infections as they occur and consider transplant only if infections become life-threatening", "Initiate prophylactic interferon-gamma and schedule transplant during adolescence"], "answer": "B", "answer_index": 1, "explanation": "Leukocyte adhesion deficiency type I is a severe immunodeficiency with absent CD18 leading to defective neutrophil adhesion and migration. The prognosis is poor without stem cell transplantation, with most patients dying before age 2 from severe infections. Urgent transplant before the onset of life-threatening infections offers the best survival. Delaying transplant beyond infancy is associated with significantly worse outcomes due to cumulative infectious complications and organ damage. G-CSF and interferon-gamma do not correct the underlying defect.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. Key stem clues—2-month-old infant, delayed umbilical cord separation >3 weeks, severe leukocytosis (WBC 80,000), recurrent skin infections, absent CD18 expression, confirmed ITGB2 mutation—are pathognomonic for leukocyte adhesion deficiency type I (LAD I). The question asks for most appropriate management. Option B (urgent stem cell transplant before onset of severe infections) is unequivocally correct: LAD I carries a poor prognosis without HSCT, with most patients dying before age 2 from overwhelming infection. Early transplant before cumulative infectious complications and organ damage offers the best survival. Alternative analysis: A inappropriately delays transplant beyond infancy, which is associated with significantly worse outcomes; C incorrectly posits that G-CSF addresses the adhesion defect; D's reactive approach risks irreversible end-organ damage; E's interferon-gamma is ineffective and adolescence is far too late. No logical flaws: stem provides sufficient discriminating detail, options are mutually exclusive, and key matches established standard of care. Medical accuracy is excellent—aligns with primary immunodeficiency guidelines and recent literature. Minimal fix: None required; item is board-ready.\",\"medical_accuracy_score\":   \"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Key stem clues—2-month-old infant, delayed umbilical cord separation >3 weeks, severe leukocytosis (WBC 80,000), recurrent skin infections, absent CD18 expression, confirmed ITGB2 mutation—are pathognomonic for leukocyte adhesion deficiency type I (LAD I). The question asks for most appropriate management. Option B (urgent stem cell transplant before onset of severe infections) is unequivocally correct: LAD I carries a poor prognosis without HSCT, with most patients dying before age 2 from overwhelming infection. Early transplant before cumulative infectious complications and organ damage offers the best survival. Alternative analysis: A inappropriately delays transplant beyond infancy, which is associated with significantly worse outcomes; C incorrectly posits that G-CSF addresses the adhesion defect; D's reactive approach risks irreversible end-organ damage; E's interferon-gamma is ineffective and adolescence is far too late. No logical flaws: stem provides sufficient discriminating detail, options are mutually exclusive, and key matches established standard of care. Medical accuracy is excellent—aligns with primary immunodeficiency guidelines and recent literature. Minimal fix: None required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-006", "question": "A 5-year-old boy with King-Denborough syndrome (dysmorphic facies, congenital myopathy, cryptorchidism) is scheduled for inguinal hernia repair. The patient has a known RYR1 mutation. Which of the following is the most appropriate anesthetic plan?", "options": ["Use total intravenous anesthesia with propofol and remifentanil, avoid dantrolene prophylaxis", "Administer dantrolene 2.5 mg/kg IV preoperatively and use sevoflurane", "Use regional anesthesia alone with spinal block, have dantrolene immediately available", "Administer dantrolene 5 mg/kg IV preoperatively and avoid all volatile agents", "Use desflurane with dantrolene 2.5 mg/kg prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "King-Denborough syndrome is associated with malignant hyperthermia susceptibility due to RYR1 mutations. However, prophylactic dantrolene is not recommended due to its own side effects. Regional anesthesia is the preferred technique when feasible, avoiding triggers entirely. If general anesthesia is necessary, total intravenous anesthesia is preferred with dantrolene immediately available, not administered prophylactically. All volatile agents are contraindicated in known MH-susceptible patients.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: M (multiple answers defensible); secondary U (underspecified). Verdict: The keyed answer C is not uniquely determinable; options A and C are both defensible. Key stem clues: 5‑year‑old with King‑Denborough syndrome and known RYR1 mutation (MH‑susceptible); inguinal hernia repair; need to avoid volatile agents and succinylcholine; dantrolene prophylaxis is not recommended. Main logical issue: The stem does not state whether regional anesthesia is feasible or preferable for this child, yet the key assumes it is the “most appropriate” choice. Without that detail, both regional (C) and TIVA (A) satisfy MH‑safe principles, making two options equally plausible. Main medical accuracy issue: The answer explanation correctly states that prophylactic dantrolene is not recommended and that all volatile agents are contraindicated. The claim that regional anesthesia is “preferred” is generally accepted but not absolute; in practice, TIVA is also a first‑line option when regional anesthesia is not practical. Minimal fix: Add a sentence to the stem such as, “Regional anesthesia is judged to be feasible and the preferred approach for this child,” to remove ambiguity.\",\n\"medical_accuracy_score\":   \t\"4\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible); secondary U (underspecified). Verdict: The keyed answer C is not uniquely determinable; options A and C are both defensible. Key stem clues: 5‑year‑old with King‑Denborough syndrome and known RYR1 mutation (MH‑susceptible); inguinal hernia repair; need to avoid volatile agents and succinylcholine; dantrolene prophylaxis is not recommended. Main logical issue: The stem does not state whether regional anesthesia is feasible or preferable for this child, yet the key assumes it is the “most appropriate” choice. Without that detail, both regional (C) and TIVA (A) satisfy MH‑safe principles, making two options equally plausible. Main medical accuracy issue: The answer explanation correctly states that prophylactic dantrolene is not recommended and that all volatile agents are contraindicated. The claim that regional anesthesia is “preferred” is generally accepted but not absolute; in practice, TIVA is also a first‑line option when regional anesthesia is not practical. Minimal fix: Add a sentence to the stem such as, “Regional anesthesia is judged to be feasible and the preferred approach for this child,” to remove ambiguity.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-007", "question": "A 32-year-old G2P1 at 34 weeks gestation presents with severe preeclampsia, HELLP syndrome, and acute decompensated peripartum cardiomyopathy (EF 25%). She is started on bromocriptine 2.5 mg twice daily to inhibit lactation. Emergency cesarean delivery is indicated. Which anesthetic technique is most appropriate?", "options": ["General anesthesia with etomidate and low-dose sevoflurane", "Spinal anesthesia with hyperbaric bupivacaine 12 mg", "Epidural anesthesia with slow titration of local anesthetic", "General anesthesia with ketamine and high-dose sevoflurane", "Local infiltration anesthesia with monitored anesthesia care"], "answer": "C", "answer_index": 2, "explanation": "Bromocriptine, a dopamine D2 agonist, can cause severe vasoconstriction and hypertensive crises, particularly when combined with general anesthetic agents. Neuraxial anesthesia (epidural) is preferred in peripartum cardiomyopathy to avoid hemodynamic fluctuations. Slow titration of epidural anesthesia allows for gradual onset and better hemodynamic stability compared to spinal anesthesia, which can cause abrupt sympathectomy and cardiovascular collapse. General anesthesia should be avoided due to the risk of bromocriptine-induced hypertension and myocardial depression.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: M (multiple answers defensible) – the stem lacks critical data (platelet count, coagulation status) to determine whether neuraxial anesthesia is safe, and the use of bromocriptine in severe preeclampsia is contraindicated, making the scenario unrealistic. Consequently, both general anesthesia (option A) and epidural (option C) can be defended depending on assumptions. Verdict on keyed answer: Not uniquely determinable; the key (C) is not reliably best. Key stem clues: severe preeclampsia/HELLP (implied thrombocytopenia), peripartum cardiomyopathy with EF 25% (high risk of hemodynamic collapse), bromocriptine (contraindicated), emergency cesarean (time pressure). Main logical issue: missing platelet count/coagulation status prevents definitive neuraxial safety assessment; unrealistic medication (bromocriptine) distracts from core anesthetic decision. Main medical accuracy issue: bromocriptine is contraindicated in severe preeclampsia; the rationale that it causes severe vasoconstriction and interacts with general anesthetics is unsupported; omission of magnesium sulfate and its anesthetic implications. Minimal fix: replace bromocriptine with a standard lactation-suppression alternative (e.g., cabergoline) and add a platelet count (e.g., 80 × 10⁹/L) to clarify neuraxial candidacy; also specify whether the patient is already receiving magnesium sulfate.\",\n\"medical_accuracy_score\":   \t\"2\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible) – the stem lacks critical data (platelet count, coagulation status) to determine whether neuraxial anesthesia is safe, and the use of bromocriptine in severe preeclampsia is contraindicated, making the scenario unrealistic. Consequently, both general anesthesia (option A) and epidural (option C) can be defended depending on assumptions. Verdict on keyed answer: Not uniquely determinable; the key (C) is not reliably best. Key stem clues: severe preeclampsia/HELLP (implied thrombocytopenia), peripartum cardiomyopathy with EF 25% (high risk of hemodynamic collapse), bromocriptine (contraindicated), emergency cesarean (time pressure). Main logical issue: missing platelet count/coagulation status prevents definitive neuraxial safety assessment; unrealistic medication (bromocriptine) distracts from core anesthetic decision. Main medical accuracy issue: bromocriptine is contraindicated in severe preeclampsia; the rationale that it causes severe vasoconstriction and interacts with general anesthetics is unsupported; omission of magnesium sulfate and its anesthetic implications. Minimal fix: replace bromocriptine with a standard lactation-suppression alternative (e.g., cabergoline) and add a platelet count (e.g., 80 × 10⁹/L) to clarify neuraxial candidacy; also specify whether the patient is already receiving magnesium sulfate.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-008", "question": "A 28-year-old Ashkenazi Jewish man develops progressive gait ataxia, dysarthria, and treatment-resistant psychosis with visual hallucinations. Hexosaminidase A activity is 5% of normal. MRI shows cerebellar atrophy. Which of the following is the most appropriate management?", "options": ["Initiate antipsychotic therapy with clozapine and refer for genetic counseling", "Enroll in clinical trial of miglustat substrate reduction therapy", "Initiate intrathecal enzyme replacement therapy with recombinant hexosaminidase A", "Prescribe donepezil for cognitive symptoms and risperidone for psychosis", "Recommend palliative care as no disease-modifying therapy exists"], "answer": "B", "answer_index": 1, "explanation": "Late-onset Tay-Sachs disease (LOTS) is a GM2 gangliosidosis with residual hexosaminidase A activity. While there is no FDA-approved therapy, miglustat has shown promise in clinical trials for substrate reduction. Intrathecal enzyme replacement is experimental and not widely available. Standard antipsychotics treat symptoms but not the underlying disease. Palliative care is premature as disease-modifying trials are ongoing.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 28-year-old Ashkenazi Jewish man with progressive cerebellar signs, treatment-resistant psychosis, and markedly reduced hexosaminidase A activity, consistent with late-onset Tay‑Sachs disease (LOTS). The key discriminating clue is the absence of any FDA‑approved disease‑modifying therapy for LOTS, while miglustat substrate‑reduction therapy is under active clinical investigation. Option B directly addresses this by recommending enrollment in a miglustat trial, which is the most appropriate disease‑directed step. Alternative choices are inferior: A and D offer only symptomatic psychiatric treatment; C proposes an experimental intrathecal enzyme replacement that is not widely available or proven; E suggests palliative care prematurely when trials are accessible. No internal contradictions exist, and the options are mutually exclusive enough to permit a single best choice. Medical accuracy is high; the item correctly notes the lack of approved therapy and the investigational status of miglustat, though the phrase “substrate reduction therapy” may be slightly imprecise for GM2 gangliosidosis. Minimal fix: add a brief clause to the stem such as ‘No disease‑modifying therapy is currently approved’ to reinforce the rationale for trial enrollment.\",\n\"medical_accuracy_score\":   \t\"4\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 28-year-old Ashkenazi Jewish man with progressive cerebellar signs, treatment-resistant psychosis, and markedly reduced hexosaminidase A activity, consistent with late-onset Tay‑Sachs disease (LOTS). The key discriminating clue is the absence of any FDA‑approved disease‑modifying therapy for LOTS, while miglustat substrate‑reduction therapy is under active clinical investigation. Option B directly addresses this by recommending enrollment in a miglustat trial, which is the most appropriate disease‑directed step. Alternative choices are inferior: A and D offer only symptomatic psychiatric treatment; C proposes an experimental intrathecal enzyme replacement that is not widely available or proven; E suggests palliative care prematurely when trials are accessible. No internal contradictions exist, and the options are mutually exclusive enough to permit a single best choice. Medical accuracy is high; the item correctly notes the lack of approved therapy and the investigational status of miglustat, though the phrase “substrate reduction therapy” may be slightly imprecise for GM2 gangliosidosis. Minimal fix: add a brief clause to the stem such as ‘No disease‑modifying therapy is currently approved’ to reinforce the rationale for trial enrollment.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-009", "question": "A 22-year-old man with schizophrenia has required risperidone 24 mg daily (8 times the standard dose) to achieve therapeutic response. Genetic testing reveals CYP2D6 ultrarapid metabolizer status (gene duplication). Which of the following monitoring parameters is most critical?", "options": ["Weekly complete blood count for agranulocytosis", "Quarterly fasting glucose and lipid panel", "Monthly prolactin level", "Baseline and annual QTc interval monitoring", "Weekly liver function tests"], "answer": "D", "answer_index": 3, "explanation": "CYP2D6 ultrarapid metabolism leads to extremely high doses of risperidone being required, resulting in accumulation of the active metabolite 9-hydroxyrisperidone. This significantly increases the risk of dose-dependent QTc prolongation and torsades de pointes. While metabolic monitoring is important, QTc prolongation is the most immediate life-threatening risk at these supratherapeutic doses. Agranulocytosis is associated with clozapine, not risperidone.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 22‑year‑old male with schizophrenia, CYP2D6 ultrarapid metabolizer (gene duplication) requiring risperidone 24 mg daily—eight times the standard dose—implies markedly increased formation of the active metabolite 9‑hydroxyrisperidone and consequently heightened dose‑dependent cardiac toxicity. Main logical issue: None; the stem provides a clear hierarchy of risks, allowing a single best answer. D is uniquely defensible because QTc prolongation and torsades represent the most immediate life‑threatening complication at supratherapeutic exposure, whereas metabolic effects (B) are longer‑term, and options A, C, and E are either misattributed (agranulocytosis with clozapine, not risperidone) or non‑standard (monthly prolactin, weekly LFTs). Main medical accuracy issue: The 24‑mg dose exceeds most approved maximums (typically 16 mg/d), and ‘annual’ QTc monitoring is less frequent than many guidelines recommend for such high‑dose therapy; nevertheless, the core principle that cardiac monitoring is the most critical parameter is sound. Minimal fix: Change the QTc monitoring interval to ‘baseline and periodic (e.g., every 3–6 months)’ to reflect the elevated risk of the ultra‑high dose.\",\n\"medical_accuracy_score\":    \t\t\t  \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t \t\t\t  \"4\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 22‑year‑old male with schizophrenia, CYP2D6 ultrarapid metabolizer (gene duplication) requiring risperidone 24 mg daily—eight times the standard dose—implies markedly increased formation of the active metabolite 9‑hydroxyrisperidone and consequently heightened dose‑dependent cardiac toxicity. Main logical issue: None; the stem provides a clear hierarchy of risks, allowing a single best answer. D is uniquely defensible because QTc prolongation and torsades represent the most immediate life‑threatening complication at supratherapeutic exposure, whereas metabolic effects (B) are longer‑term, and options A, C, and E are either misattributed (agranulocytosis with clozapine, not risperidone) or non‑standard (monthly prolactin, weekly LFTs). Main medical accuracy issue: The 24‑mg dose exceeds most approved maximums (typically 16 mg/d), and ‘annual’ QTc monitoring is less frequent than many guidelines recommend for such high‑dose therapy; nevertheless, the core principle that cardiac monitoring is the most critical parameter is sound. Minimal fix: Change the QTc monitoring interval to ‘baseline and periodic (e.g., every 3–6 months)’ to reflect the elevated risk of the ultra‑high dose.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-010", "question": "A 19-year-old woman presents with 2 weeks of progressive psychosis, culminating in nihilistic delusions that she is dead and her organs are rotting (Cotard's syndrome). CSF analysis reveals anti-NMDA receptor antibodies. Which of the following is the most appropriate initial treatment?", "options": ["High-dose oral antipsychotics and psychiatric admission", "Intravenous immunoglobulin 2 g/kg and high-dose corticosteroids", "Electroconvulsive therapy for refractory psychosis", "Plasmapheresis alone", "Rituximab monotherapy"], "answer": "B", "answer_index": 1, "explanation": "NMDA receptor encephalitis is a treatable autoimmune encephalitis that frequently presents with severe psychiatric symptoms including Cotard's syndrome. First-line immunotherapy with IVIG and high-dose corticosteroids is essential and should not be delayed for psychiatric treatment alone. ECT has no role in the acute autoimmune phase. Plasmapheresis alone is less effective than combination therapy, and rituximab is reserved for refractory cases after first-line therapy.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V (Valid). Verdict: The keyed answer B is the correct best choice. The stem provides classic features of anti‑NMDA receptor encephalitis: young adult female, subacute progressive psychosis with Cotard’s delusions, and CSF anti‑NMDA receptor antibodies. Current consensus (Lancet Neurol 2016, NEJM 2018) recommends prompt first‑line immunotherapy with IVIG plus high‑dose corticosteroids. Option B matches this recommendation. Alternative A (antipsychotics alone) would delay disease‑modifying therapy; C (ECT) is not initial; D (plasmapheresis alone) is less effective than combination therapy; E (rituximab) is reserved for refractory cases. No internal contradictions, no missing critical details, and all distractors are plausible but clearly inferior. Therefore the item supports a single best answer and the key is correct. Medical accuracy: fully aligned with modern guidelines and board expectations. Score 5. Logical validity: true. Minimal fix: none required.\",\n\"medical_accuracy_score\":  \t \t \t \t \t \t \t \t \t \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: The keyed answer B is the correct best choice. The stem provides classic features of anti‑NMDA receptor encephalitis: young adult female, subacute progressive psychosis with Cotard’s delusions, and CSF anti‑NMDA receptor antibodies. Current consensus (Lancet Neurol 2016, NEJM 2018) recommends prompt first‑line immunotherapy with IVIG plus high‑dose corticosteroids. Option B matches this recommendation. Alternative A (antipsychotics alone) would delay disease‑modifying therapy; C (ECT) is not initial; D (plasmapheresis alone) is less effective than combination therapy; E (rituximab) is reserved for refractory cases. No internal contradictions, no missing critical details, and all distractors are plausible but clearly inferior. Therefore the item supports a single best answer and the key is correct. Medical accuracy: fully aligned with modern guidelines and board expectations. Score 5. Logical validity: true. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-011", "question": "A 14-year-old girl with short stature, obesity, and developmental delay presents with seizures. Labs show hypocalcemia (6.8 mg/dL), hyperphosphatemia, and elevated PTH (250 pg/mL). She has brachydactyly and subcutaneous calcifications. Which of the following is the most appropriate diagnostic test?", "options": ["GNAS gene sequencing for activating mutations", "Methylation-specific PCR of the GNAS locus", "Calcium-sensing receptor gene analysis", "Vitamin D 25-hydroxy level", "Thyroid function tests"], "answer": "B", "answer_index": 1, "explanation": "Pseudohypoparathyroidism type 1A is caused by maternally inherited inactivating mutations in GNAS with loss of imprinting. The diagnosis requires methylation-specific PCR to demonstrate abnormal GNAS methylation patterns, which distinguishes it from other forms of PHP and from pseudopseudohypoparathyroidism. Standard gene sequencing alone is insufficient as it doesn't assess imprinting. The biochemical pattern (elevated PTH with hypocalcemia) is characteristic of PTH resistance.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. Key stem clues: The biochemical pattern of PTH resistance (hypocalcemia with hyperphosphatemia despite markedly elevated PTH) combined with Albright hereditary osteodystrophy phenotype (brachydactyly, short stature, obesity, subcutaneous calcifications) and developmental delay specifically points to pseudohypoparathyroidism type 1A (PHP1A). The question targets diagnostic testing. Methylation-specific PCR of the GNAS locus (option B) is the appropriate first-line test to detect the imprinting defect that defines PHP1A, distinguishing it from pseudopseudohypoparathyroidism (PPHP) and PHP1B. Alternative critique: Option A is flawed—PHP1A requires inactivating mutations, and sequencing alone cannot assess imprinting; C addresses calcium-sensing receptor disorders with opposite biochemistry; D fails to explain PTH resistance or AHO features; E is unrelated to the primary diagnosis. No logical deficiencies: stem provides adequate positive and negative discriminators, and answer choices permit clear differentiation. Medical accuracy is gold-standard: phenotype-genotype correlation, imprinting pathophysiology, and recommended diagnostic algorithm are all current and precise. Minimal fix: None required.\",\"medical_accuracy_score\":  \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: The biochemical pattern of PTH resistance (hypocalcemia with hyperphosphatemia despite markedly elevated PTH) combined with Albright hereditary osteodystrophy phenotype (brachydactyly, short stature, obesity, subcutaneous calcifications) and developmental delay specifically points to pseudohypoparathyroidism type 1A (PHP1A). The question targets diagnostic testing. Methylation-specific PCR of the GNAS locus (option B) is the appropriate first-line test to detect the imprinting defect that defines PHP1A, distinguishing it from pseudopseudohypoparathyroidism (PPHP) and PHP1B. Alternative critique: Option A is flawed—PHP1A requires inactivating mutations, and sequencing alone cannot assess imprinting; C addresses calcium-sensing receptor disorders with opposite biochemistry; D fails to explain PTH resistance or AHO features; E is unrelated to the primary diagnosis. No logical deficiencies: stem provides adequate positive and negative discriminators, and answer choices permit clear differentiation. Medical accuracy is gold-standard: phenotype-genotype correlation, imprinting pathophysiology, and recommended diagnostic algorithm are all current and precise. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-012", "question": "A 4-year-old boy with newly diagnosed high-risk T-cell ALL develops tumor lysis syndrome with uric acid 12 mg/dL and creatinine 2.5 mg/dL. He is found to have G6PD deficiency. Which of the following is the most appropriate management?", "options": ["Administer rasburicase 0.2 mg/kg IV daily", "Initiate aggressive hydration and allopurinol, avoid rasburicase", "Perform emergent hemodialysis", "Administer rasburicase 0.1 mg/kg with concurrent blood transfusion", "Initiate alkalinization of urine to pH >7.5"], "answer": "B", "answer_index": 1, "explanation": "Rasburicase is contraindicated in G6PD deficiency as it can precipitate severe hemolysis by generating hydrogen peroxide. In G6PD-deficient patients with tumor lysis syndrome, aggressive hydration and allopurinol are the mainstays of therapy. Hemodialysis is reserved for refractory cases. Alkalinization is no longer routinely recommended due to risk of calcium phosphate precipitation. The risk of hemolysis outweighs the benefits of rasburicase in this population.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (Valid). Verdict: Correct best answer. Key discriminating clues: G6PD deficiency, high uric acid (12 mg/dL), elevated creatinine (2.5 mg/dL), high-risk T-cell ALL. These indicate tumor lysis syndrome (TLS) with renal involvement in a patient with G6PD deficiency, for whom rasburicase is contraindicated due to risk of severe hemolysis from hydrogen peroxide generation. The appropriate initial management is aggressive IV hydration plus allopurinol (xanthine oxidase inhibitor) to reduce uric acid production. Hemodialysis is reserved for refractory TLS; alkalinization is no longer routine due to calcium phosphate precipitation risk. Option B aligns with current guidelines (e.g., NCCN, ASH) and is the only option that avoids rasburicase while providing effective therapy. Options A and D propose rasburicase, which is contraindicated; C is overly aggressive for initial management; E is outdated. The patient’s age and high-risk ALL subtype increase TLS risk, but do not alter the G6PD-driven contraindication. No internal contradictions; all options are plausible but clearly inferior. No medical inaccuracies. Minimal fix: none required.\",\n\"medical_accuracy_score\":   \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. Key discriminating clues: G6PD deficiency, high uric acid (12 mg/dL), elevated creatinine (2.5 mg/dL), high-risk T-cell ALL. These indicate tumor lysis syndrome (TLS) with renal involvement in a patient with G6PD deficiency, for whom rasburicase is contraindicated due to risk of severe hemolysis from hydrogen peroxide generation. The appropriate initial management is aggressive IV hydration plus allopurinol (xanthine oxidase inhibitor) to reduce uric acid production. Hemodialysis is reserved for refractory TLS; alkalinization is no longer routine due to calcium phosphate precipitation risk. Option B aligns with current guidelines (e.g., NCCN, ASH) and is the only option that avoids rasburicase while providing effective therapy. Options A and D propose rasburicase, which is contraindicated; C is overly aggressive for initial management; E is outdated. The patient’s age and high-risk ALL subtype increase TLS risk, but do not alter the G6PD-driven contraindication. No internal contradictions; all options are plausible but clearly inferior. No medical inaccuracies. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-013", "question": "A 6-year-old boy has significant difficulties with social communication, including inappropriate responses in conversation and difficulty understanding non-literal language. He does not have restricted interests or repetitive behaviors. Which assessment tool is most appropriate to differentiate Social Communication Disorder from autism spectrum disorder?", "options": ["Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)", "Social Communication Questionnaire (SCQ)", "Children's Communication Checklist (CCC-2)", "Social Responsiveness Scale (SRS)", "Gilliam Autism Rating Scale (GARS)"], "answer": "C", "answer_index": 2, "explanation": "The Children's Communication Checklist-2 specifically evaluates pragmatic language skills and social communication deficits while distinguishing these from restricted/repetitive behaviors characteristic of autism. The ADOS-2 and SCQ are designed to identify autism, not to differentiate SCD from ASD. The SRS measures social impairment but doesn't assess the full diagnostic criteria distinction. GARS is a screening tool for autism, not a differential diagnostic instrument.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: M (Multiple answers defensible). Verdict: Not uniquely determinable. Stem describes a 6-year-old with pragmatic language deficits but no RRBs, consistent with SCD. The query 'most appropriate to differentiate SCD from ASD' is ambiguous: ADOS-2 (A) is the gold-standard ASD diagnostic that directly assesses both social communication and RRBs, enabling differential diagnosis by ruling out ASD. CCC-2 (C) specifically measures pragmatic language deficits central to SCD but lacks RRB assessment, making it less suitable for differentiation despite targeting the core SCD domain. The rationale's claim that CCC-2 'distinguishes these from restricted/repetitive behaviors' is factually inaccurate—a significant medical error that misrepresents the tool's capabilities. Both A and C are defensible depending on interpretation of 'differentiate' as comprehensive diagnostic assessment versus targeted pragmatic evaluation. Minimal fix: Rephrase stem to 'Which tool best assesses pragmatic language deficits in suspected SCD?' or revise rationale to accurately reflect CCC-2's scope and acknowledge ADOS-2's role in differential diagnosis.\",\"medical_accuracy_score\":   \"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (Multiple answers defensible). Verdict: Not uniquely determinable. Stem describes a 6-year-old with pragmatic language deficits but no RRBs, consistent with SCD. The query 'most appropriate to differentiate SCD from ASD' is ambiguous: ADOS-2 (A) is the gold-standard ASD diagnostic that directly assesses both social communication and RRBs, enabling differential diagnosis by ruling out ASD. CCC-2 (C) specifically measures pragmatic language deficits central to SCD but lacks RRB assessment, making it less suitable for differentiation despite targeting the core SCD domain. The rationale's claim that CCC-2 'distinguishes these from restricted/repetitive behaviors' is factually inaccurate—a significant medical error that misrepresents the tool's capabilities. Both A and C are defensible depending on interpretation of 'differentiate' as comprehensive diagnostic assessment versus targeted pragmatic evaluation. Minimal fix: Rephrase stem to 'Which tool best assesses pragmatic language deficits in suspected SCD?' or revise rationale to accurately reflect CCC-2's scope and acknowledge ADOS-2's role in differential diagnosis.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-014", "question": "A 3-year-old boy of Palestinian descent presents with chronic multifocal osteomyelitis, dyserythropoietic anemia, and neutrophilic dermatosis. Genetic testing reveals LPIN2 mutation (Majeed syndrome). Which NSAID is most effective for long-term management?", "options": ["Ibuprofen 10 mg/kg every 6 hours", "Naproxen 5 mg/kg twice daily", "Indomethacin 1-2 mg/kg/day in divided doses", "Celecoxib 50 mg twice daily", "Aspirin 10 mg/kg every 4 hours"], "answer": "C", "answer_index": 2, "explanation": "Majeed syndrome is an autoinflammatory disease characterized by chronic recurrent multifocal osteomyelitis. Indomethacin is the NSAID of choice due to its potent anti-inflammatory effects and superior efficacy in autoinflammatory bone diseases compared to other NSAIDs. The response to indomethacin can also serve as a diagnostic clue. Other NSAIDs are less effective, and aspirin should be avoided in children due to Reye syndrome risk. COX-2 inhibitors have limited data in this rare condition.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The stem's core discriminating feature is the rare autoinflammatory disease Majeed syndrome (LPIN2 mutation) with chronic recurrent multifocal osteomyelitis. The keyed answer C (indomethacin) is defensible based on historical literature describing superior efficacy in autoinflammatory bone diseases and potential diagnostic response, though this concept is somewhat outdated. Alternative A (ibuprofen) and B (naproxen) lack this specific association in the rare disease context. D (celecoxib) has limited pediatric data for this condition. E (aspirin) is correctly excluded due to Reye syndrome risk in children. The item is logically coherent with one defensible best answer. Medical accuracy is sound but not gold standard: while indomethacin is effective, modern pediatric rheumatology often favors naproxen for better tolerability with similar efficacy, and evidence is limited by disease rarity. The 'most effective' framing slightly overstates the certainty. Minimal fix: Rephrase question to 'Which NSAID is historically considered first-line for long-term management?' or add 'based on documented disease-specific response patterns' to temper the superiority claim.\",\"medical_accuracy_score\":    \"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The stem's core discriminating feature is the rare autoinflammatory disease Majeed syndrome (LPIN2 mutation) with chronic recurrent multifocal osteomyelitis. The keyed answer C (indomethacin) is defensible based on historical literature describing superior efficacy in autoinflammatory bone diseases and potential diagnostic response, though this concept is somewhat outdated. Alternative A (ibuprofen) and B (naproxen) lack this specific association in the rare disease context. D (celecoxib) has limited pediatric data for this condition. E (aspirin) is correctly excluded due to Reye syndrome risk in children. The item is logically coherent with one defensible best answer. Medical accuracy is sound but not gold standard: while indomethacin is effective, modern pediatric rheumatology often favors naproxen for better tolerability with similar efficacy, and evidence is limited by disease rarity. The 'most effective' framing slightly overstates the certainty. Minimal fix: Rephrase question to 'Which NSAID is historically considered first-line for long-term management?' or add 'based on documented disease-specific response patterns' to temper the superiority claim.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-015", "question": "A 2-year-old toddler ingests a 0.3 mg clonidine transdermal patch. Six hours later, he becomes lethargic with bradycardia (HR 60) and hypotension (BP 70/40). Which of the following is the most appropriate management?", "options": ["Administer activated charcoal and observe", "Initiate atropine 0.02 mg/kg IV for bradycardia", "Administer naloxone 0.1 mg/kg IV bolus followed by continuous infusion", "Initiate dopamine infusion at 5 mcg/kg/min", "Perform gastric lavage and administer whole bowel irrigation"], "answer": "C", "answer_index": 2, "explanation": "Clonidine toxicity causes central alpha-2 agonist-mediated CNS depression and sympathetic outflow inhibition. Naloxone competitively displaces clonidine from opioid receptors, reversing both respiratory depression and hemodynamic instability. A continuous infusion is often required due to clonidine's long half-life. Atropine may not effectively counteract the central mechanism of bradycardia. Activated charcoal is ineffective after 6 hours, and dopamine treats symptoms but not the underlying toxicity.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: K (Miskeyed). Verdict: The keyed answer C (naloxone) is not the most appropriate management for a clonidine‑overdosed toddler with hypotension and bradycardia. Key stem clues: 2‑year‑old, 0.3 mg clonidine patch ingestion, 6‑hour delay, lethargy, HR 60, BP 70/40. The central problem is combined bradycardia and hypotension due to central α‑2 agonism. Naloxone may reverse CNS/respiratory depression but has no reliable effect on hemodynamics; current guidelines recommend atropine for bradycardia and a vasopressor (e.g., dopamine) for hypotension. Option D (dopamine infusion) addresses both heart rate and blood pressure, making it the best choice. Option B (atropine) treats bradycardia only, leaving hypotension unaddressed. The provided explanation incorrectly claims naloxone reverses hemodynamic instability, which is inaccurate. Therefore the item is miskeyed. Minimal fix: Replace the key with D and revise the rationale to state that dopamine (or another vasopressor) is the first‑line agent for clonidine‑induced hypotension/bradycardia in a pediatric patient, with atropine as adjunct for bradycardia.\",\n\"medical_accuracy_score\":  \t\t \t\"2\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer C (naloxone) is not the most appropriate management for a clonidine‑overdosed toddler with hypotension and bradycardia. Key stem clues: 2‑year‑old, 0.3 mg clonidine patch ingestion, 6‑hour delay, lethargy, HR 60, BP 70/40. The central problem is combined bradycardia and hypotension due to central α‑2 agonism. Naloxone may reverse CNS/respiratory depression but has no reliable effect on hemodynamics; current guidelines recommend atropine for bradycardia and a vasopressor (e.g., dopamine) for hypotension. Option D (dopamine infusion) addresses both heart rate and blood pressure, making it the best choice. Option B (atropine) treats bradycardia only, leaving hypotension unaddressed. The provided explanation incorrectly claims naloxone reverses hemodynamic instability, which is inaccurate. Therefore the item is miskeyed. Minimal fix: Replace the key with D and revise the rationale to state that dopamine (or another vasopressor) is the first‑line agent for clonidine‑induced hypotension/bradycardia in a pediatric patient, with atropine as adjunct for bradycardia.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-016", "question": "A 6-year-old girl with Freeman-Sheldon syndrome (whistling face syndrome) requires anesthesia for tendon release surgery. She has microstomia, micrognathia, and a short neck. Which airway management strategy is most appropriate?", "options": ["Awake fiberoptic intubation with nasal approach", "Inhalational induction with sevoflurane followed by video laryngoscopy", "Intravenous induction with propofol and direct laryngoscopy", "Use of laryngeal mask airway without intubation", "Perform tracheostomy under local anesthesia before surgery"], "answer": "A", "answer_index": 0, "explanation": "Freeman-Sheldon syndrome is associated with severe facial contractures, microstomia, and limited neck extension, making mask ventilation and intubation extremely difficult. Awake fiberoptic intubation is the gold standard to secure the airway before induction of anesthesia. Inhalational induction risks airway obstruction in a patient who cannot be bag-mask ventilated effectively. Direct laryngoscopy is likely to fail due to limited mouth opening and neck mobility. LMA placement is challenging due to facial contractures.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: U (Underspecified) – the stem lacks a critical detail about the feasibility of bag‑mask ventilation, which is required to determine whether inhalational induction is safe. Without this information, both awake fiberoptic intubation (A) and inhalational induction with video laryngoscopy (B) are defensible, leading to multiple plausible best answers. Verdict on keyed answer: Not uniquely determinable. Key stem clues: Freeman‑Sheldon syndrome, microstomia, micrognathia, short neck – all predict a difficult airway, but the stem does not state whether mask ventilation is expected to be ineffective or whether the child can cooperate for an awake procedure. Main logical issue: Missing information about bag‑mask ventilation and patient cooperation creates ambiguity between options A and B. Main medical accuracy issue: The answer explanation labels awake fiberoptic intubation as the gold standard for a 6‑year‑old, yet current pediatric difficult‑airway guidelines emphasize inhalational induction with sevoflurane while maintaining spontaneous ventilation as the preferred initial approach in young children; awake fiberoptic intubation is reserved for older, cooperative patients. Minimal fix: Add a phrase such as \\\"Bag‑mask ventilation is anticipated to be ineffective due to severe facial contractures\\\" to the stem, making awake fiberoptic intubation the clear best choice.\",\n\"medical_accuracy_score\":   \t\"2\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) – the stem lacks a critical detail about the feasibility of bag‑mask ventilation, which is required to determine whether inhalational induction is safe. Without this information, both awake fiberoptic intubation (A) and inhalational induction with video laryngoscopy (B) are defensible, leading to multiple plausible best answers. Verdict on keyed answer: Not uniquely determinable. Key stem clues: Freeman‑Sheldon syndrome, microstomia, micrognathia, short neck – all predict a difficult airway, but the stem does not state whether mask ventilation is expected to be ineffective or whether the child can cooperate for an awake procedure. Main logical issue: Missing information about bag‑mask ventilation and patient cooperation creates ambiguity between options A and B. Main medical accuracy issue: The answer explanation labels awake fiberoptic intubation as the gold standard for a 6‑year‑old, yet current pediatric difficult‑airway guidelines emphasize inhalational induction with sevoflurane while maintaining spontaneous ventilation as the preferred initial approach in young children; awake fiberoptic intubation is reserved for older, cooperative patients. Minimal fix: Add a phrase such as \"Bag‑mask ventilation is anticipated to be ineffective due to severe facial contractures\" to the stem, making awake fiberoptic intubation the clear best choice.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-017", "question": "A 45-year-old woman on methadone 120 mg daily for chronic pain develops torsades de pointes with QTc 580 ms. She is hemodynamically unstable. Which medication is most appropriate for acute management?", "options": ["Amiodarone 150 mg IV bolus", "Magnesium sulfate 2 g IV bolus", "Isoproterenol infusion", "Lidocaine 1 mg/kg IV bolus", "Procainamide 15 mg/kg IV infusion"], "answer": "C", "answer_index": 2, "explanation": "Torsades de pointes in acquired long QT syndrome is a pause-dependent arrhythmia. Isoproterenol increases heart rate, shortening the QT interval and preventing the short-long RR interval sequence that precipitates TdP. While magnesium is first-line for stable TdP, isoproterenol is preferred in hemodynamically unstable patients. Amiodarone and procainamide further prolong the QT interval and are contraindicated. Lidocaine is ineffective for TdP.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: K (Miskeyed). Verdict: The keyed answer C (isoproterenol) is incorrect; the best answer is B (magnesium sulfate). The stem provides a clear scenario of drug-induced TdP with prolonged QTc and hemodynamic instability. Current guidelines (AHA/ACC) recommend immediate cardioversion for unstable TdP, but when a medication is requested, magnesium sulfate 2 g IV bolus is first-line therapy. Isoproterenol is only indicated for pause-dependent TdP with bradycardia, which is not mentioned. The explanation erroneously claims isoproterenol is preferred in unstable patients, contradicting standard teaching. Alternative options are correctly excluded: amiodarone and procainamide prolong QT, lidocaine is ineffective. The item is otherwise logically coherent and discriminating, but the key is wrong. Minimal fix: Change the correct answer to B and update the rationale to state magnesium is first-line for TdP; isoproterenol is reserved for pause-dependent cases with bradycardia.\",\n\"medical_accuracy_score\":   \t\"2\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer C (isoproterenol) is incorrect; the best answer is B (magnesium sulfate). The stem provides a clear scenario of drug-induced TdP with prolonged QTc and hemodynamic instability. Current guidelines (AHA/ACC) recommend immediate cardioversion for unstable TdP, but when a medication is requested, magnesium sulfate 2 g IV bolus is first-line therapy. Isoproterenol is only indicated for pause-dependent TdP with bradycardia, which is not mentioned. The explanation erroneously claims isoproterenol is preferred in unstable patients, contradicting standard teaching. Alternative options are correctly excluded: amiodarone and procainamide prolong QT, lidocaine is ineffective. The item is otherwise logically coherent and discriminating, but the key is wrong. Minimal fix: Change the correct answer to B and update the rationale to state magnesium is first-line for TdP; isoproterenol is reserved for pause-dependent cases with bradycardia.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-018", "question": "A mother is undergoing forensic psychiatric evaluation for allegedly causing medical illness in her child (factitious disorder imposed on another). She denies any intentional behavior. Which assessment tool is specifically designed to detect malingering and factitious behavior in forensic settings?", "options": ["Minnesota Multiphasic Personality Inventory-2 (MMPI-2)", "Structured Interview of Reported Symptoms (SIRS)", "Miller Forensic Assessment of Symptoms Test (M-FAST)", "Personality Assessment Inventory (PAI)", "Hare Psychopathy Checklist-Revised (PCL-R)"], "answer": "C", "answer_index": 2, "explanation": "The M-FAST is a brief screening tool specifically designed to assess malingering and symptom exaggeration in forensic evaluations. It has validated cut-off scores for detecting factitious presentations. While the MMPI-2 and PAI have validity scales, they are not as specific for factitious disorders. The SIRS assesses malingered psychosis, not factitious behavior. The PCL-R assesses psychopathy traits, not symptom validity.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: M (Multiple answers defensible). Verdict: Not uniquely determinable—both C and B are specifically designed forensic malingering tools. Stem clues: forensic psychiatric evaluation for FDIA, denial of intent, need for specialized assessment tool. The M-FAST is a validated brief screening instrument for malingering in forensic contexts. However, the SIRS (option B) is equally 'specifically designed' for forensic malingering detection, making it a defensible alternative. The rationale contains a medical inaccuracy: SIRS assesses broad malingering domains (rare symptoms, improbable combinations), not solely 'malingered psychosis.' This mischaracterization artificially eliminates a viable option. Without specifying brief screening versus comprehensive assessment, the stem cannot discriminate between C and B. Minimal fix: Add 'brief screening' to the stem ('Which brief screening tool...') to favor M-FAST, or replace B with a non-forensic tool and correct the rationale to reflect SIRS's actual scope.\",\"medical_accuracy_score\":   \"2\",\"logical_validity\": false,\"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (Multiple answers defensible). Verdict: Not uniquely determinable—both C and B are specifically designed forensic malingering tools. Stem clues: forensic psychiatric evaluation for FDIA, denial of intent, need for specialized assessment tool. The M-FAST is a validated brief screening instrument for malingering in forensic contexts. However, the SIRS (option B) is equally 'specifically designed' for forensic malingering detection, making it a defensible alternative. The rationale contains a medical inaccuracy: SIRS assesses broad malingering domains (rare symptoms, improbable combinations), not solely 'malingered psychosis.' This mischaracterization artificially eliminates a viable option. Without specifying brief screening versus comprehensive assessment, the stem cannot discriminate between C and B. Minimal fix: Add 'brief screening' to the stem ('Which brief screening tool...') to favor M-FAST, or replace B with a non-forensic tool and correct the rationale to reflect SIRS's actual scope.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-019", "question": "A 35-year-old man with treatment-resistant schizophrenia on clozapine 500 mg daily develops severe nocturnal sialorrhea with recurrent aspiration pneumonia. Which medication is most effective for this side effect?", "options": ["Benztropine 2 mg at bedtime", "Atropine ophthalmic solution 1% administered sublingually at bedtime", "Amantadine 100 mg twice daily", "Glycopyrrolate 1 mg twice daily", "Ipratropium bromide nasal spray"], "answer": "B", "answer_index": 1, "explanation": "Clozapine-induced sialorrhea is mediated by muscarinic M3 receptor agonism. Sublingual atropine ophthalmic solution provides potent anticholinergic effects locally, reducing salivation without significant systemic side effects. Glycopyrrolate and benztropine have poor CNS penetration and are less effective for nocturnal sialorrhea. Amantadine is ineffective for this side effect. Ipratropium nasal spray has minimal effect on salivation.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem correctly identifies severe clozapine-induced nocturnal sialorrhea with aspiration pneumonia risk. Key discriminating features are nocturnal timing and need to avoid CNS side effects in schizophrenia. Both B (sublingual atropine) and D (glycopyrrolate) are clinically valid options, but glycopyrrolate is widely considered first-line due to its peripheral selectivity and lack of CNS penetration—advantages the rationale mischaracterizes. The rationale contains major factual errors: clozapine sialorrhea is M4-mediated (not M3), benztropine crosses the BBB (contrary to claim), and glycopyrrolate is particularly effective for nocturnal symptoms (not less effective). This makes the 'most effective' claim ambiguous and unsupported. Amantadine and ipratropium are appropriately excluded. Minimal fix: Change key to D and revise rationale to state glycopyrrolate's peripheral selectivity makes it ideal for nocturnal sialorrhea in schizophrenia, with atropine as a reasonable alternative.\",\"medical_accuracy_score\":    \"2\",\"logical_validity\": false,\"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem correctly identifies severe clozapine-induced nocturnal sialorrhea with aspiration pneumonia risk. Key discriminating features are nocturnal timing and need to avoid CNS side effects in schizophrenia. Both B (sublingual atropine) and D (glycopyrrolate) are clinically valid options, but glycopyrrolate is widely considered first-line due to its peripheral selectivity and lack of CNS penetration—advantages the rationale mischaracterizes. The rationale contains major factual errors: clozapine sialorrhea is M4-mediated (not M3), benztropine crosses the BBB (contrary to claim), and glycopyrrolate is particularly effective for nocturnal symptoms (not less effective). This makes the 'most effective' claim ambiguous and unsupported. Amantadine and ipratropium are appropriately excluded. Minimal fix: Change key to D and revise rationale to state glycopyrrolate's peripheral selectivity makes it ideal for nocturnal sialorrhea in schizophrenia, with atropine as a reasonable alternative.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed129", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed129-020", "question": "A 40-year-old Puerto Rican woman presents to the emergency department with acute episode of screaming, crying, trembling, and feeling detached from her body after receiving news of her mother's death. Family reports this is an 'ataque de nervios.' Which of the following is the most appropriate DSM-5 diagnosis?", "options": ["Panic disorder, with cultural idiom", "Dissociative identity disorder", "Acute stress disorder", "Other specified trauma- and stressor-related disorder (ataque de nervios)", "No psychiatric diagnosis; this is a culturally normative expression of grief"], "answer": "D", "answer_index": 3, "explanation": "'Ataque de nervios' is recognized in DSM-5 as a cultural syndrome that can be classified under 'Other specified trauma- and stressor-related disorder' when symptoms cause clinically significant distress. It is not considered a normative expression of grief when it results in functional impairment. While it shares features with panic and dissociative disorders, the specific cultural framework warrants its own diagnostic category. Acute stress disorder requires more persistent symptoms beyond the acute episode.", "generator_model": "kimi-k2-thinking", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict: The keyed answer D is the correct best answer. Key stem clues: acute emotional episode (screaming, crying, trembling) with depersonalization triggered by mother's death; family identifies 'ataque de nervios'; Puerto Rican ethnicity establishes cultural context; ED presentation signals clinical significance. DSM-5 specifically lists 'ataque de nervios' as a cultural concept of distress coded under Other specified trauma- and stressor-related disorder when causing clinically significant impairment. Alternative options are correctly excluded: A (panic disorder requires recurrent unexpected attacks), B (dissociative identity disorder requires identity disruption), C (acute stress disorder requires symptoms persisting 3 days–1 month), and E (denies diagnosis when presentation warrants clinical attention). No logical contradictions or underspecification—ED presentation reasonably implies distress/impairment. Medical accuracy aligns with DSM-5 cultural syndromes. Minimal fix: None required; optional addition of 'resulting in functional impairment' to stem would explicitly satisfy diagnostic threshold but is implied by ED visit.\",\"medical_accuracy_score\":  \"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: The keyed answer D is the correct best answer. Key stem clues: acute emotional episode (screaming, crying, trembling) with depersonalization triggered by mother's death; family identifies 'ataque de nervios'; Puerto Rican ethnicity establishes cultural context; ED presentation signals clinical significance. DSM-5 specifically lists 'ataque de nervios' as a cultural concept of distress coded under Other specified trauma- and stressor-related disorder when causing clinically significant impairment. Alternative options are correctly excluded: A (panic disorder requires recurrent unexpected attacks), B (dissociative identity disorder requires identity disruption), C (acute stress disorder requires symptoms persisting 3 days–1 month), and E (denies diagnosis when presentation warrants clinical attention). No logical contradictions or underspecification—ED presentation reasonably implies distress/impairment. Medical accuracy aligns with DSM-5 cultural syndromes. Minimal fix: None required; optional addition of 'resulting in functional impairment' to stem would explicitly satisfy diagnostic threshold but is implied by ED visit.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]